Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome

Use of 3,4-Diaminopyridine(3 4-DAP)in the Treatment of Lambert-Eaton Syndrome (LEMS)

To learn more about the effect of 3, 4-Diaminopyridine (3,4-DAP) on patient diagnosed with Lambert-Eaton myasthenic syndrome (LEMS).

Inclusion Criteria:

• Age 18 years or older,
• Diagnosed with LEMS,
• If female, have a negative pregnancy test, and
• If premenopausal, be willing to practice an effective form of birth control during the study,
• Tested and found by ECG not to have a prolonged QT syndrome,
• Agree to have a second ECG at the time of peak drug effect,
• Has understood and signed the Informed Consent.

Exclusion Criteria:

• Is known to have a sensitivity to 3, 4-DAP,

• Has a history of:

  1. past or current seizures,
  2. cardiac arrhythmia,
  3. hepatic, renal or hematologic disease, or
  4. severe asthma,

• Is believed by the investigator to be unable to comply with the protocol.